je.st
news
Tag: the
Southwest Airlines: A Dividend Champion In The Making?
2016-04-17 19:27:56| Airlines - Topix.net
With the market quickly approaching all time highs, stocks are becoming more expensive everyday. The list of high quality, undervalued companies is growing thinner and thinner.
Tags: the
making
champion
southwest
Drew Clark: Utah Republicans continue to provide a responsible example to the nation
2016-04-17 11:35:35| Apparel - Topix.net
Can the anger-filled movement inspired by the Boston revolt eventually mature into a Philadelphia vision of constructive constitutionalism? It must. Utah is the most Republican state in the nation, based on quadrennial presidential election voting.
OPINION: Why Obama's crack down on corporate mergers is the right...
2016-04-17 04:08:26| Biotech - Topix.net
Hail to the chief. President Obama is giving big business the business, holding the corporate giants' feet to the fire - and as a small business owner who struggles to survive in an environment of acquisitions and mergers, I'm grateful.
Tags: the
right
opinion
corporate
Coca-Cola and PepsiCo Have a Big Problem. So Did the Best Investment in the Past Half-Century.
2016-04-16 14:34:36| Beverages - Topix.net
Coca-Cola has introduced its low-cal, cane-sugar and stevia sweetened Coca-Cola Life soda to win back consumers worried about artificial sweeteners and/or excessive sugar consumption. Source: Coca-Cola.
Merck Announces Results From Phase 3 Studies of ZEPATIER (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress
2016-04-16 07:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C (HCV) patients with inherited blood disorders (C-EDGE IBLD) and in patients with a history of intravenous drug use who are receiving opioid agonist therapy (C-EDGE CO-STAR), respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
results
international
studies
Sites : [734] [735] [736] [737] [738] [739] [740] [741] [742] [743] [744] [745] [746] [747] [748] [749] [750] [751] [752] [753] next »